{"text": "Disease - free survival : Time from randomization to first occurrence of an IDFS event including second primary non - breast cancer or contralateral or ipsilateral ductal carcinoma in situ [ Time Frame : up to 10 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "36.459496"}
{"text": "LCSG-772 randomized 141 patients with resected stage II or III adenocarcinoma or large - cell carcinoma of the lung to six cycles of CAP chemotherapy or to a control group that received no chemotherapy .", "label": "", "metadata": {}, "score": "38.99689"}
{"text": "A cancer survivor is eligible provided that the following criteria are met : .The patient has undergone potentially curative therapy for all prior malignancies , .", "label": "", "metadata": {}, "score": "39.678444"}
{"text": "Inclusion Criteria : .Histologic proof of breast cancer ( invasive ductal or lobular carcinoma ) .Breast sarcoma and lymphoma are not eligible .Clinical diagnosis of locally advanced breast cancer ( Stage IIB ( T3,N0,M0 ) , Stage IIIA , IIIB , or IIIC , according to American Joint Committee on Cancer ( AJCC ) Tumour - Node - Metastasis ( TNM )", "label": "", "metadata": {}, "score": "39.855347"}
{"text": "Breast Cancer .Intervention ICMJE .Behavioral : Lifestyle intervention .Women randomized to the lifestyle intervention arm will receive an intervention program that consists of individual weight loss , diet and physical activity goals , incorporated into a 2 year standardized , structured telephone and mail - based intervention .", "label": "", "metadata": {}, "score": "40.94312"}
{"text": "Patients with metastatic breast cancer identified by immunohistochemistry ( IHC ) are not eligible .Patient randomized to ALND must undergo ALND within 42 days of their SLND .", "label": "", "metadata": {}, "score": "41.473457"}
{"text": "Patients with multifocal or bilateral disease are eligible .History of osteoporosis : Women diagnosed with osteoporosis may participate in this trial provided they are receiving appropriate therapy or if they have declined therapy .", "label": "", "metadata": {}, "score": "42.177937"}
{"text": "Other medical endpoints such as diabetes , cardiovascular disease , arthritis , fasting biomarkers at 12 months compared to baseline ( for women participating in a biospecimen substudy )", "label": "", "metadata": {}, "score": "43.63924"}
{"text": "Patients are stratified according to adjuvant chemotherapy ( yes vs no ) , number of positive nodes ( 0 - 3 vs at least 4 ) , and endovaginal sonogram endometrial stripe ( less than 5 mm vs at least 5 mm ) .", "label": "", "metadata": {}, "score": "44.180378"}
{"text": "Compare endometrial pathologic diagnoses ( proliferative changes , simple or cystic hyperplasia , complex adenomatous hyperplasia , hyperplasia with atypia , and carcinoma ) in postmenopausal women with breast carcinoma treated with adjuvant tamoxifen who are randomly assigned to medroxyprogesterone acetate ( MA ) vs observation .", "label": "", "metadata": {}, "score": "44.256104"}
{"text": "Patients must be randomized within 84 days ( 12 weeks ) of surgical resection ; if more than one surgical procedure is required to render the patient disease - free , the patient must be randomized within 12 weeks of the last surgery .", "label": "", "metadata": {}, "score": "44.7772"}
{"text": "Documentation of hepatitis B virus and hepatitis C virus serology is required .Exclusion Criteria : .Stage IV ( metastatic ) breast cancer .History of any prior ( ipsi- or contralateral breast cancer except lobular carcinoma in situ .", "label": "", "metadata": {}, "score": "44.979313"}
{"text": "[ 7 ] Overall , 85 % of participants had T2 , N0 and 15 % had T1 , N1 tumors .Five - year survival was 55 % in both groups .", "label": "", "metadata": {}, "score": "45.35544"}
{"text": "[ 10 ] In this study , 488 patients were randomized to receive four cycles of adjuvant chemotherapy with cisplatin and etoposide and concurrent radiation ( 50.4 Gy ) or to a similar PORT regimen .", "label": "", "metadata": {}, "score": "45.416054"}
{"text": "Patients are eligible for inclusion in this NIS if they have taken anastrozole either upfront or following two to three years of tamoxifen treatment ( \" switch \" ) for at least three and not more than six months prior to offering an individual participation in this program .", "label": "", "metadata": {}, "score": "45.521038"}
{"text": "Evidence of metastatic breast cancer following a standard tumor staging work - up .Known human immunodeficiency viral ( HIV ) infection .Serious intercurrent infections or non - malignant medical illness that are uncontrolled or the control of which may be jeopardized by this therapy .", "label": "", "metadata": {}, "score": "46.15251"}
{"text": "[ Time Frame : 12 months ] [ Designated as safety issue : Yes ] .The patient population will include postmenopausal women with hormone - receptor positive primary breast cancer scheduled for adjuvant upfront endocrine treatment with anastrozole or following two to three years of tamoxifen treatment ( \" switch \" ) according to the current SmPC ( Appendix C ) .", "label": "", "metadata": {}, "score": "46.36808"}
{"text": "However , five RCTs that have now been reported indicate that adjuvant chemotherapy is effective , at least in certain subgroups of resectable patients .Moreover , numerous meta - analyses have also reported a positive effect from adjuvant treatment .", "label": "", "metadata": {}, "score": "46.759254"}
{"text": "To identify baseline IHC and expression biomarkers predictive of response to treatment , with response determined by extent of Ki67 reduction .Subsets showing the greatest reduction in Ki67 would be the most likely candidates for non - operative treatment in future studies .", "label": "", "metadata": {}, "score": "46.86136"}
{"text": "[ 11 ] Eight trials utilizing a cisplatin - based adjuvant chemotherapy regimen showed an overall 13 % proportional reduction in the risk of death among those receiving adjuvant chemotherapy .", "label": "", "metadata": {}, "score": "47.13557"}
{"text": "Eligibility Criteria ICMJE .Inclusion Criteria : .HER2-positive breast cancer .Histologically confirmed invasive breast carcinoma .Clinical stage T1 - 4/N0 - 3/M0 at presentation ( patients with T1a / bN0 tumors will not be eligible ) .", "label": "", "metadata": {}, "score": "48.52155"}
{"text": "Overall , 5-year survival is estimated to be 10 % in Europe and 9 % in developing countries .[ 1 ] .Among patients with early - stage non - small - cell lung cancer ( NSCLC ) , the most powerful predictor of long - term survival is the ability to achieve complete surgical resection .", "label": "", "metadata": {}, "score": "48.859463"}
{"text": "LCSG-791 randomized 172 patients with incompletely resected NSCLC , as defined either by the presence of tumor in the highest resected mediastinal node , or by a positive margin .", "label": "", "metadata": {}, "score": "49.141674"}
{"text": "Participants undergo definitive breast surgery 4 -6 weeks from last dose of FAC / FEC - regimen .Tumors removed by either lumpectomy with axillary dissection ( i.e. breast conservation surgery ) or modified radical mastectomy ( i.e. mastectomy with axillary clearance ) .", "label": "", "metadata": {}, "score": "49.284863"}
{"text": "Post - menopausal woman with a diagnosis of invasive breast cancer ( T1 - 3,pN0 - 2,M0 ) for which definitive surgery was performed during the previous 36 months .", "label": "", "metadata": {}, "score": "49.411182"}
{"text": "A positive pregnancy test at baseline .Pregnant or breastfeeding .No active or chronic infection with human immunodeficiency virus ( HIV ) , hepatitis B , or hepatitis C ; patients must have negative testing for HIV , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) within 4 weeks prior to randomization Patients undergo axillary lymph node dissection involving removal of at least level I and II nodes , followed by whole - breast radiotherapy ( exclusive of a third supraclavicular field ) 5 days a week for a maximum of 7 weeks .", "label": "", "metadata": {}, "score": "50.343353"}
{"text": "For example , data reported by Mountain in 1986 that were used to establish the International Staging System for lung cancer included 5-year survival rates of 64 % and 45 % for patients with pathologic stage I or II disease , respectively ( Table 2 ) .", "label": "", "metadata": {}, "score": "50.51212"}
{"text": "Patients with breast - sparing procedure must have received or be planning to receive radiotherapy at start of tamoxifen treatment .No endometrial simple or cystic hyperplasia , proliferative changes , complex ( adenomatous ) or atypical hyperplasia , or carcinoma .", "label": "", "metadata": {}, "score": "50.525684"}
{"text": "Pregnancy / nursing status : Not pregnant or nursing .Required Initial Laboratory Values : .Reviews .The standard of care with regard to adjuvant chemotherapy of lung cancer has changed remarkably over the past 3 years .", "label": "", "metadata": {}, "score": "50.526604"}
{"text": "Patients must not have had any infectious disease vaccination ( e.g. , standard influenza , H1N1 influenza , pneumococcal , meningococcal , or tetanus toxoid ) within 4 weeks prior to randomization .", "label": "", "metadata": {}, "score": "51.41915"}
{"text": "Detailed Description : .OBJECTIVES : .Primary objectives : .Long term : To assess whether overall survival for patients randomized to Arm 2 ( no immediate ALND ) is essentially equivalent to ( or better than ) than that for patients assigned to Arm 1 ( completion ALND ) .", "label": "", "metadata": {}, "score": "51.451828"}
{"text": "Concomitant treatment with drugs known to affect sex hormonal status and tamoxifen .Patients with ductal carcinoma in situ ( DCIS ) without primary diagnosis of early breast cancer ( M0 ) .", "label": "", "metadata": {}, "score": "51.550293"}
{"text": "Pathologic Complete Response ( pCR )[ Time Frame : 4 -6 weeks from last dose of FAC / FEC - regimen . ][ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "52.131035"}
{"text": "Stage I , IIA , or IIB ( T1 - 3 , N0 - 1 , M0 ) .No recurrent invasive breast cancer .Ductal carcinoma in situ ( DCIS ) .", "label": "", "metadata": {}, "score": "52.298424"}
{"text": "Other : Quality - of - Life Assessment .Patients receive high - dose recombinant interferon alpha-2b IV on days 1 - 5 , 8 - 12 , 15 - 19 , and 22 - 26 in the absence of disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "52.37597"}
{"text": "Leitch AM , McCall L , Beitsch P , et al .: Factors influencing accrual to ACOSOG Z0011 , a randomized phase III trial of axillary dissection vs. observation for sentinel node positive breast cancer .", "label": "", "metadata": {}, "score": "52.451332"}
{"text": "These are two additional radiographic parameters which may also biological response to therapy .To determine practice patterns of adjuvant hormonal and radiation therapy in patients who complete neoadjuvant letrozole therapy for DCIS .", "label": "", "metadata": {}, "score": "52.5315"}
{"text": "Patient must have access to radiation therapy .A sentinel lymph node must be identified that contains metastatic breast cancer as documented by frozen section , touch prep , or H&E staining on permanent section .", "label": "", "metadata": {}, "score": "52.673225"}
{"text": "At least 2 months since bilateral oophorectomy prior to breast cancer diagnosis .4 - 12 months since last menstrual period and FSH elevated to postmenopausal range .", "label": "", "metadata": {}, "score": "52.754494"}
{"text": "The three categories are complete response , near complete response and chemotherapy resistance .A complete pathologic response ( pCR ) refers to complete absence of invasive cancer .", "label": "", "metadata": {}, "score": "52.934063"}
{"text": "Patients diagnosed with DCIS on the basis of surgical biopsy are not eligible for this study .All patients must have a clip placed , either at the time of the diagnostic biopsy or at the time of the baseline MRI prior to the start of treatment .", "label": "", "metadata": {}, "score": "53.223587"}
{"text": "Ability to undergo neoadjuvant chemotherapy .Exclusion Criteria : .Evidence of metastatic disease ( identified on chest x - ray , liver ultrasound , bone scan or other imaging tests ) ; .", "label": "", "metadata": {}, "score": "53.50345"}
{"text": "To assess quality - of - life and musculoskeletal symptoms associated with neoadjuvant letrozole for ER positive DCIS .Patients will be followed up to 6 months post - surgery .", "label": "", "metadata": {}, "score": "53.72196"}
{"text": "The patient who had BCT ( segmental mastectomy ) performed previously , and is now referred to the local investigator for SLND , is eligible if the BCT was less than or equal to 60 days prior to the SLND .", "label": "", "metadata": {}, "score": "53.73134"}
{"text": "A Randomized , Multicenter , Open - Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy .", "label": "", "metadata": {}, "score": "53.803642"}
{"text": "Randomized Trials and Meta - Analysis Published Prior to 2003 .Three cisplatin - based adjuvant randomized trials sponsored by the Lung Cancer Study Group ( LCSG ) are among the best known older studies in the area of adjuvant chemotherapy of lung cancer .", "label": "", "metadata": {}, "score": "53.851883"}
{"text": "NOTE : previous radiation therapy , including after the surgical resection , is allowed as long as 21 days have elapsed between the radiation and initiation of this adjuvant systemic therapy .", "label": "", "metadata": {}, "score": "54.626205"}
{"text": "Subjects receiving hormone replacement treatment ( HRT ) are eligible if this therapy is discontinued at least 2 weeks before starting study treatment .Treatment for DCIS is allowed , such as surgery , hormonal therapy and radiotherapy .", "label": "", "metadata": {}, "score": "55.16255"}
{"text": "Any T N3 M0 .Stage IV .M1a . M1b .Patients with disease recurrence after adequate surgical excision of the original primary cutaneous / unknown primary melanoma are allowed even if they do n't fit the strict staging criteria , but only as follows : .", "label": "", "metadata": {}, "score": "55.28634"}
{"text": "Nonetheless , the 5 % survival advantage observed in the 1995 meta - analysis with cisplatin - based chemotherapy provided an incentive for conducting additional randomized trials in this area .", "label": "", "metadata": {}, "score": "55.339394"}
{"text": "No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer , carcinoma in situ of the cervix , or stage I or II cancer currently in complete remission .", "label": "", "metadata": {}, "score": "55.36242"}
{"text": "The patient population will include postmenopausal women with hormone - receptor positive primary breast cancer receiving adjuvant endocrine treatment with anastrozole upfront or following two to three years of tamoxifen therapy ( \" switch \" ) according to the current SmPC ( Appendix C ) .", "label": "", "metadata": {}, "score": "55.47766"}
{"text": "[ 9 ] Stage distribution included 70 % with stage III , 26 % with stage II , and 3 % with stage I disease .", "label": "", "metadata": {}, "score": "55.66425"}
{"text": "No prior neoadjuvant / adjuvant therapy for current DCIS diagnosis .Contraindication to MRI : No contraindications to breast MRI .DCIS must be visible on MRI based on central review .", "label": "", "metadata": {}, "score": "55.70227"}
{"text": "Patient is lactating ( breastfeeding ) .Patient has been previously treated with chemotherapy , estrogen receptor antagonists ( i.e. , Tamoxifen ) or selective estrogen receptor modulators ( SERMs , i.e. , Raloxifene ) for this invasive breast cancer .", "label": "", "metadata": {}, "score": "55.964973"}
{"text": "This 2-arm , randomized , open - label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy .", "label": "", "metadata": {}, "score": "55.99198"}
{"text": "Histologically confirmed primary invasive adenocarcinoma of the breast .Clinical stage breast cancer T2 - 3 , N0 - 3 , M0 .Negative HER-2/neu expression as determined by local hospital laboratory using Fluorescence In Situ Hybridization ( FISH ) , or is less or equal to 1 + using Immunohistochemistry ( IHC ) .", "label": "", "metadata": {}, "score": "56.095345"}
{"text": "Progressive disease during preoperative therapy .Treatment with any anti - cancer investigational drug within 28 days prior to commencing study treatment .History of other malignancy within the last 5 years except for appropriately treated carcinoma in situ of the cervix , non - melanoma skin carcinoma , Stage I uterine cancer , or other non - breast malignancies with a similar outcome to those mentioned above .", "label": "", "metadata": {}, "score": "56.19952"}
{"text": "Patient has three or more positive sentinel nodes by frozen section , touch prep , or H&E staining on permanent section .Choosing to participate in a study is an important personal decision .", "label": "", "metadata": {}, "score": "56.356525"}
{"text": "Treatment decisions for patients participating in this study including assessments or supportive therapy during follow - up visits will also follow guidelines and remain independent of the program .", "label": "", "metadata": {}, "score": "56.361626"}
{"text": "Retrospective assessment of incidence of pre - existing arthralgias before start of anastrozole treatment , stratified by upfront and switch therapy .[ Time Frame : 12 months ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "56.3871"}
{"text": "Experimental : Individualized Lifestyle Intervention .Women randomized to the individualized lifestyle intervention arm will receive an intervention program that consists of individual weight loss , diet and physical activity goals , incorporated into a 2 year standardized , structured telephone and mail - based intervention .", "label": "", "metadata": {}, "score": "56.483154"}
{"text": "Distant recurrence - free interval : Time from randomization to date of distant breast cancer recurrence [ Time Frame : up to 10 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "56.685314"}
{"text": "History of exposure to the following cumulative doses of anthracyclines : .Cardiopulmonary dysfunction as defined by protocol .Prior treatment with trastuzumab emtansine .Current severe , uncontrolled systemic disease .", "label": "", "metadata": {}, "score": "57.03666"}
{"text": "While a considerable risk of recurrence and death following resection has long provided a powerful rationale for adjuvant treatment , research in the area of adjuvant chemotherapy has never received the same priority in NSCLC as it has in other common cancers , particularly breast and colorectal cancer .", "label": "", "metadata": {}, "score": "57.20874"}
{"text": "Note : A patient can be registered to this study if they have a cytologic diagnosis suggestive of carcinoma from a fine needle aspiration ( FNA ) of a palpable or non - palpable breast lesion and the investigator believes the breast lesion is clinically suspicious for invasive breast carcinoma .", "label": "", "metadata": {}, "score": "57.301735"}
{"text": "Women must not be pregnant or breast - feeding ; all females of childbearing potential must have a blood test or urine study during screening to rule out pregnancy .", "label": "", "metadata": {}, "score": "57.43754"}
{"text": "Stage distribution included 31 % with T1 , N0 disease , 62 % with T2 , N0 disease , and 7 % with T3 , N0 NSCLC .", "label": "", "metadata": {}, "score": "57.518024"}
{"text": "Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Prevention .", "label": "", "metadata": {}, "score": "57.548286"}
{"text": "Known recurrence of breast cancer ( local , regional or distant ) at any time prior to study entry .Prior in situ cancer of the breast is not a reason for exclusion .", "label": "", "metadata": {}, "score": "58.079987"}
{"text": "Locally Advanced Breast Cancer ( LABC ) .Intervention ICMJE .Procedure : FLT PET and BOLD MRI scan .Eligible consenting patients with LABC receiving neoadjuvant chemotherapy ( NA CT ) will undergo FLT PET , BOLD MRI , and clinical examination of the involved breast including ipsilateral axillary and supraclavicular nodes to assess the treatment response to chemotherapy ( CT ) .", "label": "", "metadata": {}, "score": "58.17911"}
{"text": "Subsequently , I will address recent randomized trials that have led to a change in clinical practice in resectable NSCLC .In the discussion section , I will attempt to define the current state of the art in adjuvant therapy and to articulate major unanswered questions .", "label": "", "metadata": {}, "score": "58.646687"}
{"text": "Incidence of cardiac events : Death from cardiac cause or severe chronic heart failure ( NYHA Class III or IV )[ Time Frame : up to 10 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "58.646706"}
{"text": "Patient unwilling or unable to provide informed consent .Gender .Female .Ages .Not Provided .Accepts Healthy Volunteers .No .Contacts ICMJE .", "label": "", "metadata": {}, "score": "58.71829"}
{"text": "The primary and secondary objectives are provided below .Primary objective : .To estimate the mean change in MRI tumor volume from pretreatment to completion of preoperative endocrine therapy in estrogen receptor - positive ( ER+ ) ductal carcinoma in situ ( DCIS ) , as well as to determine whether 3-month change in volume correlates with 6-month change .", "label": "", "metadata": {}, "score": "59.15332"}
{"text": "Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Prevention .", "label": "", "metadata": {}, "score": "59.26844"}
{"text": "RFS [ Time Frame : From randomization to the time of disease recurrence or death from any cause , assessed up to 20 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "59.414284"}
{"text": "Patient 's clinical stage must be documented as tumor size less than 5 cm , with no palpable nodes and no evidence of metastatic disease ( T1 or T2 N0 M0 ; see appendices for staging criteria ) and the tumor documented as amenable to lumpectomy .", "label": "", "metadata": {}, "score": "59.911217"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01593020 .Breast Neoplasms Breast Diseases Neoplasms Neoplasms by Site Skin Diseases Cyclophosphamide Doxorubicin Epirubicin Fluorouracil Liposomal doxorubicin Paclitaxel Alkylating Agents Antibiotics , Antineoplastic Antimetabolites Antimetabolites , Antineoplastic .", "label": "", "metadata": {}, "score": "59.913643"}
{"text": "Known hormone - receptor status .Eastern Cooperative Oncology Group ( ECOG ) performance status 0 or 1 .Adequate hematologic , renal and liver function .", "label": "", "metadata": {}, "score": "60.12781"}
{"text": "Serious digestive and/or absorptive problems , including inflammatory bowel disease and chronic diarrhea that preclude adherence to the study diet .Cardiovascular , respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity .", "label": "", "metadata": {}, "score": "60.1593"}
{"text": "RATIONALE : It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen .Detailed Description .", "label": "", "metadata": {}, "score": "60.452118"}
{"text": "This sample size will provide 80 % power ( type 1 error 0.05 2-tailed ) to detect a hazard ratio ( HR ) for DFS of 0.74 - 0.76 in the weight loss intervention arm .", "label": "", "metadata": {}, "score": "60.655247"}
{"text": "Adequate excision : surgical removal of all clinically evident disease in the breast and lymph nodes as specified in protocol .Pathological evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy .", "label": "", "metadata": {}, "score": "60.69847"}
{"text": "Criteria .Inclusion Criteria : .Histologically / cytologically confirmed primary diagnosis of early breast cancer ( M0 ) with hormone sensitive tumour ( ER+ve and/or PgR+ve ) .", "label": "", "metadata": {}, "score": "60.78605"}
{"text": "Patient has a medical contraindication to ALND or is considered a poor surgical risk due to a non - malignant systemic disease ( cardiovascular , renal , etc . ) that would preclude the treatment options .", "label": "", "metadata": {}, "score": "60.93125"}
{"text": "The two - sample t - test will be used to compare continuous measurements and Chi - square test will be used to compare the categorical outcomes between the two treatment groups .", "label": "", "metadata": {}, "score": "61.171524"}
{"text": "The two - sample t - test will be used to compare continuous measurements and Chi - square test will be used to compare the categorical outcomes between the two treatment groups .", "label": "", "metadata": {}, "score": "61.171524"}
{"text": "Detailed Description .Not Provided .Study Type ICMJE .Interventional .Study Phase .Not Provided .Study Design ICMJE .Allocation : Non - Randomized Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Diagnostic .", "label": "", "metadata": {}, "score": "61.445778"}
{"text": "Willingness to have core biopsies and/or FNA performed before the start of study treatment and at the end of 12 week on treatment .Exclusion Criteria : .", "label": "", "metadata": {}, "score": "61.57552"}
{"text": "Patients must not have an active infection requiring current treatment with parenteral antibiotics .Patients must not have a documented history of inflammatory bowel disease ( including ulcerative colitis and Crohn 's disease ) or diverticulitis ( history of diverticulosis is allowed ) .", "label": "", "metadata": {}, "score": "61.876682"}
{"text": "Distant disease - free survival [ Time Frame : 8 years ] [ Designated as safety issue : No ] .Weight at 6 , 12 , 24 , 36 , 48 and 60 months compared to baseline [ Time Frame : 5 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "62.18196"}
{"text": "Original Primary Outcome Measures ICMJE ( submitted : January 8 , 2011 ) .Overall survival of patients treated with adjuvant ipilimumab versus high - dose recombinant interferon alfa-2b [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "62.19966"}
{"text": "Interventional .Study Phase .Phase 2 .Study Design ICMJE .Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "62.294117"}
{"text": "Brief Title ICMJE .A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy ( KATHERINE ) .", "label": "", "metadata": {}, "score": "62.42166"}
{"text": "Other : Quality - of - Life Assessment .Biological : Recombinant Interferon Alfa-2b .Patients receive induction low - dose ipilimumab IV over 90 minutes on day 1 .", "label": "", "metadata": {}, "score": "62.522964"}
{"text": "Incidence of toxicity assessed using the National Cancer Institute ( NCI ) Common Terminology Criteria for Adverse Events ( CTCAE ) version 4.0 [ Time Frame : Up to 70 days after completion of study treatment ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "62.57844"}
{"text": "Patients then receive maintenance high - dose recombinant interferon alfa-2b subcutaneously ( SC ) on days 1 , 3 , and 5 .Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "62.83511"}
{"text": "Prior treatment : .No prior surgical excision in the index breast for current DCIS diagnosis of DCIS .Any exogenous hormone therapy must be completed 4 weeks prior to registration .", "label": "", "metadata": {}, "score": "63.068497"}
{"text": "NOTE :A subpectoral implant is allowed .Patient has concurrent invasive bilateral breast malignancies .Patient has clinically and radiologically identified multi - centric disease that is not amenable to a single lumpectomy .", "label": "", "metadata": {}, "score": "63.159542"}
{"text": "Radiotherapy and/or hormone therapy will be given in addition if indicated .Detailed Description .Not Provided .Study Type ICMJE .Interventional .Study Phase .", "label": "", "metadata": {}, "score": "63.27243"}
{"text": "Detailed Description .PRIMARY OBJECTIVES : . II .SECONDARY OBJECTIVES : . I. To evaluate safety and tolerability of post - operative adjuvant ipilimumab therapy given at either 10 mg / kg ( HIP ) or 3 mg / kg ( LIP ) .", "label": "", "metadata": {}, "score": "63.39533"}
{"text": "A Phase III Randomized Study of Adjuvant Ipilimumab Anti - CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma .Brief Summary .", "label": "", "metadata": {}, "score": "63.660347"}
{"text": "Patients are followed every 6 months for 2 years and then annually thereafter .PROJECTED ACCRUAL : A total of 330 patients ( 165 per arm ) will be accrued for this study .", "label": "", "metadata": {}, "score": "63.872856"}
{"text": "To assess radiographic - pathologic correlation between MRI findings and histopathology , including the prevalence of occult invasive cancer in patients undergoing neoadjuvant endocrine therapy for DCIS .", "label": "", "metadata": {}, "score": "63.908134"}
{"text": "[ Time Frame : 12 months ] [ Designated as safety issue : No ] .Identification of factors influencing and correlating to treatment - emergent arthralgias [ Time Frame : 12 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "64.25838"}
{"text": "All patients receive adjuvant oral tamoxifen daily for five years .Arm I : Patients undergo observation .Arm II : Patients receive oral medroxyprogesterone acetate on days 1 - 14 .", "label": "", "metadata": {}, "score": "64.30861"}
{"text": "Active Comparator : Radiotherapy .Patients undergo breast radiotherapy only .Patients may receive adjuvant systemic therapy at the discretion of the treating physician .Patients are followed up at 30 days , at 6 , 12 , 18 , 30 , and 36 months , and then annually for a total of 10 years .", "label": "", "metadata": {}, "score": "64.32042"}
{"text": "Inclusion Criteria : .If for some reason a CT can not be done , an MRI may be done instead ; any other imaging studies if performed ( eg , bone scan ) must show no evidence of disease .", "label": "", "metadata": {}, "score": "64.389114"}
{"text": "This study also showed significantly better survival at 1 year in the CAP arm ( 68 % vs 54 % ) , although with longer follow - up the significant survival advantage disappeared .", "label": "", "metadata": {}, "score": "64.45093"}
{"text": "OS [ Time Frame : From randomization to date of death , assessed up to 20 years ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "64.50745"}
{"text": "Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity .( adult accrual has completed to Arms A , B , and C as of 8/15/2014 ) .", "label": "", "metadata": {}, "score": "64.62367"}
{"text": "Intervention : Biological : Ipilimumab .Experimental : Arm E ( ages 12 - 17 , recombinant interferon alfa-2b ) .Patients receive high - dose recombinant interferon alpha-2b IV on days 1 - 5 , 8 - 12 , 15 - 19 , and 22 - 26 in the absence of disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "64.8062"}
{"text": "There is a 3 and 6 month disease evaluation by MRI of both breasts .If the DCIS has grown , the patient will have surgery to remove it and will continue to take letrozole until the day before surgery .", "label": "", "metadata": {}, "score": "64.87898"}
{"text": "Copies of the operative and pathology reports must be submitted as part of the registration process .Patient must be available for follow - up .", "label": "", "metadata": {}, "score": "65.32814"}
{"text": "Candidate for adjuvant tamoxifen therapy .PATIENT CHARACTERISTICS : .Age : . Adult .Sex : .Female .Menopausal status : .Postmenopausal defined as : .", "label": "", "metadata": {}, "score": "65.38525"}
{"text": "A Randomized Comparison Of Medroxyprogesterone Acetate ( MA )And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen , Phase III .", "label": "", "metadata": {}, "score": "65.47992"}
{"text": "Detailed Description .Treatment with letrozole begins within 21 days of registration , and only after notification has been received from the UCSF Breast MRI Research Laboratory that the baseline MRI is acceptable .", "label": "", "metadata": {}, "score": "65.726395"}
{"text": "December 2006 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .DISEASE CHARACTERISTICS : .One of the following histologically proven diagnoses : .", "label": "", "metadata": {}, "score": "66.17547"}
{"text": "Prior definitive local treatment of primary lesion ( mastectomy or breast - sparing procedure with radiotherapy ) and either axillary node or sentinel node biopsy .", "label": "", "metadata": {}, "score": "66.198715"}
{"text": "Patients are followed up at 30 days , at 6 , 12 , 18 , 30 , and 36 months , and then annually for a total of 10 years .", "label": "", "metadata": {}, "score": "66.24044"}
{"text": "Paget 's disease of the nipple .No sarcoma , lymphoma , or apocrine , adenocystic , or squamous cell cancer of the breast .Currently free of breast cancer ( no evidence of disease ) .", "label": "", "metadata": {}, "score": "66.44443"}
{"text": "Menopausal status : Patients must be postmenopausal defined as : .Surgical menopause with bilateral oophorectomy ( at least 28 days must elapse from surgery to time of study registration ) .", "label": "", "metadata": {}, "score": "66.49332"}
{"text": "Significant concurrent medical problems that result in the patient being unfit for surgery ( e.g. uncontrolled diabetes , active cardiac disease , severe chronic obstructive pulmonary disease ) ; .", "label": "", "metadata": {}, "score": "66.55846"}
{"text": "Detailed Description .Secondary outcomes include overall survival , distant disease - free survival , weight change , health - related quality of life ( HRQOL ) , selected non - cancer medical events and biologic factors ( notably insulin ) .", "label": "", "metadata": {}, "score": "66.799866"}
{"text": "Patients will have a MRI for disease evaluation at months 3 and 6 .All patients will continue to take study drug until the day prior to surgery , whether at month 3 or at month 6 or may stop if they experience unacceptable toxicity .", "label": "", "metadata": {}, "score": "67.106705"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00857012 Blood Oxygen Level Dependent Magnetic Resonance Imaging ( BOLD MRI ) and Fluorothymidine Positron Emission Tomography ( FLT PET ) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy ( IMPACT ) .", "label": "", "metadata": {}, "score": "67.15194"}
{"text": "In case of a previous therapy with tamoxifen ( switch - therapy ) , duration of tamoxifen treatment for at least two and up to three years .", "label": "", "metadata": {}, "score": "67.19867"}
{"text": "No gross or microscopically positive margins except : .Invasive cancer or DCIS at the focal margin treated with definitive radiotherapy .Gross or LCIS at the final margin .", "label": "", "metadata": {}, "score": "67.231125"}
{"text": "Monoclonal antibodies , such as ipilimumab , may interfere with the ability of tumor cells to grow and spread .Interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and other cancers .", "label": "", "metadata": {}, "score": "67.65988"}
{"text": "T1 - 4b N2b M0 .T1 - 4b N2c M0 .Stage IIIC .T1 - 4b N1b M0 .T1 - 4b N2b M0 .", "label": "", "metadata": {}, "score": "67.68305"}
{"text": "Other : .No prior or current participation in an adjuvant intergroup trial .Gender .Female .Ages .18 Years and older .Accepts Healthy Volunteers .", "label": "", "metadata": {}, "score": "67.874344"}
{"text": "In this study , the standard chemotherapy being given is either 5-fluorouracil , epirubicin , and cyclophosphamide ( called FEC ) or 5-fluorouracil , doxorubicin , and cyclophosphamide ( called FAC ) .", "label": "", "metadata": {}, "score": "68.12226"}
{"text": "Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity .( ages 12 - 17 ) .Intervention : Biological : Recombinant Interferon Alfa-2b .", "label": "", "metadata": {}, "score": "68.13449"}
{"text": "Descriptive Information .Brief Title ICMJE .Ipilimumab or High - Dose Interferon Alfa-2b in Treating Patients With High - Risk Stage III - IV Melanoma That Has Been Removed by Surgery .", "label": "", "metadata": {}, "score": "68.14343"}
{"text": "On a worldwide basis , lung cancer is both the most common cancer and most common cause of cancer mortality .In the year 2002 , there were an estimated 1,350,000 new cases of lung cancer , and an estimated 1,179,000 lung cancer deaths .", "label": "", "metadata": {}, "score": "68.26538"}
{"text": "Chi - square test will be used for AE comparisons .Original Secondary Outcome Measures ICMJE ( submitted : January 8 , 2011 ) .Recurrence - free survival [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "68.26945"}
{"text": "Compliance with study procedures .Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .", "label": "", "metadata": {}, "score": "68.58519"}
{"text": "Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity .( closed accrual as of 4/4/14 ) ( adult accrual has completed to Arms A , B , and C as of 8/15/2014 ) .", "label": "", "metadata": {}, "score": "68.6264"}
{"text": "Clinical stage : Tis or T1mi N0 , M0 .Hormone receptor status : DCIS must express estrogen and/or progesterone receptor , as determined by immunohistochemical methods on the diagnostic pathology sample , according to the local institution 's standard protocol .", "label": "", "metadata": {}, "score": "68.6529"}
{"text": "Patient or the patient 's legally acceptable representative must provide a signed and dated written informed consent prior to registration and any study - related procedures .", "label": "", "metadata": {}, "score": "69.332405"}
{"text": "On the other hand , numerous important questions remain .The next several sections review key recent trials that have begun to answer these questions .", "label": "", "metadata": {}, "score": "69.43554"}
{"text": "Toxicity incidence rate and 95 % confidence interval for each type will be presented .The percentages of patients experiencing the worst degree toxicities ( highest grade event per adverse event [ AE ] type per patient ) will be evaluated and the distribution of the worst degree toxicities will be compared among the treatment arms .", "label": "", "metadata": {}, "score": "69.49529"}
{"text": "Indeed , the ACS estimates that lung cancer will be responsible for 162,460 cancer deaths in the US in 2006 .[ 2 ] By way of comparison , an estimated 156,250 deaths were expected from colorectal cancer , breast cancer , pancreatic cancer , and prostate cancer combined .", "label": "", "metadata": {}, "score": "69.557755"}
{"text": "This article reviews the recent randomized trials that have contributed to a change in the state of the art , as well as some of the methodologic problems that may have confounded their proper interpretation .", "label": "", "metadata": {}, "score": "70.28581"}
{"text": "ARM E : Patients receive induction high - dose recombinant interferon alfa-2b IV over 20 minutes on days 1 - 5 , 8 - 12 , 15 - 19 , and 22 - 26 in the absence of disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "70.337074"}
{"text": "Characterize the incidence of spontaneous regression and progression of simple or cystic hyperplasia in these patients .Characterize endometrial biopsy results using different endometrial stripe width cut - off points , for cases in which the width is at least 5 mm by endovaginal ultrasound in patients receiving tamoxifen .", "label": "", "metadata": {}, "score": "70.43999"}
{"text": "OUTLINE : This is a randomized study .Patients are randomized to one of two treatment arms .PLEASE NOTE :Patients registered to this study may undergo intra - operative or post\u00acoperative randomization .", "label": "", "metadata": {}, "score": "70.73564"}
{"text": "Starting adjuvant tamoxifen for five years OR .Started tamoxifen within 28 days prior to study and planning to receive adjuvant tamoxifen for five years .", "label": "", "metadata": {}, "score": "70.808716"}
{"text": "NOTE :This may be obtained in either the study - specific informed consent or in a separate authorization form and must be obtained from the patient prior to study registration .", "label": "", "metadata": {}, "score": "70.98489"}
{"text": "In contrast , however , a smaller study conducted at Helsinki University Central Hospital in Finland , with a very similar design to LCSG-801 , was the only individual randomized trial to report a significant survival advantage .", "label": "", "metadata": {}, "score": "71.205795"}
{"text": "Recurrence in the form of in - transit or satellite metastases or distant skin / subcutaneous , nodal , or lung metastases that are completely surgically resected with free margins .", "label": "", "metadata": {}, "score": "71.26745"}
{"text": "Interventions : .Drug : letrozole .Procedure : MRI .Procedure : conventional surgery .Not Provided .Recruitment Status ICMJE .Recruiting .Estimated Enrollment ICMJE .", "label": "", "metadata": {}, "score": "71.27706"}
{"text": "5 ] ( It should be noted that control participants did receive an immunotherapy regimen , consisting of intrapleural bacillus Calmette - Gu\u00e9rin ( BCG ) and levamisole , for which there is no other evidence for efficacy . )", "label": "", "metadata": {}, "score": "71.46149"}
{"text": "Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "71.54367"}
{"text": "[ Time Frame : 12 months ] [ Designated as safety issue : Yes ] .Incidence of arthralgia and arthralgia characteristics within the 1st year of anastrozole therapy stratified by upfront and switch therapy and assessment of the relationship of arthralgia incidence and arthralgia characteristics to patients compliance .", "label": "", "metadata": {}, "score": "71.61342"}
{"text": "Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment .Official Title : .", "label": "", "metadata": {}, "score": "71.77687"}
{"text": "Psychiatric disorders or conditions that , in the opinion of the investigator , would preclude participation in the study intervention ( e.g. untreated major depression or psychosis , substance abuse , severe personality disorder ) .", "label": "", "metadata": {}, "score": "71.90118"}
{"text": "It is estimated that lung cancer will be responsible for 28.8 % of all cancer deaths in the US in 2006 , despite the fact that it represents only 12.5 % of all new cancers .", "label": "", "metadata": {}, "score": "72.2281"}
{"text": "Procedure : adjuvant therapy .Not Provided .Recruitment Information .Recruitment Status ICMJE .Completed .Enrollment ICMJE .Completion Date .December 2009 .", "label": "", "metadata": {}, "score": "72.44018"}
{"text": "Compliance with study procedures .[ Time Frame : 8 years ] [ Designated as safety issue : No ] .Original Secondary Outcome Measures ICMJE ( submitted : April 19 , 2007 ) .", "label": "", "metadata": {}, "score": "72.940186"}
{"text": "Describe the associations among change in gene expression , receptor status , endometrial abnormality , length of tamoxifen exposure , and prior chemotherapy in these patients .", "label": "", "metadata": {}, "score": "72.944374"}
{"text": "Current Secondary Outcome Measures ICMJE ( submitted : November 11 , 2010 ) .Pathologic response [ Time Frame : 6 months ( approximately ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "73.2001"}
{"text": "Distant disease - free survival .Weight at 6 , 12 , 24 , 36 , 48 and 60 months compared to baseline .Health - related quality of life at 6 , 12 , 24 , 36 , 48 and 60 months compared to baseline .", "label": "", "metadata": {}, "score": "73.51869"}
{"text": "Beginning on week 24 , patients receive maintenance low - dose ipilimumab IV over 90 minutes on day 1 .Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "73.704254"}
{"text": "Beginning on week 24 , patients receive maintenance low - dose ipilimumab IV over 90 minutes on day 1 .Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "73.704254"}
{"text": "Inability to lie supine for imaging with Positron Emission Tomography ( PET ) ; .Any contraindication to undergoing Magnetic Resonance Imaging ( MRI ) or PET ; .", "label": "", "metadata": {}, "score": "73.96817"}
{"text": "Any known active liver disease , e.g. due to HBV , HCV , autoimmune hepatic disorders , or sclerosing cholangitis .Concurrent serious uncontrolled infections or known infection with HIV .", "label": "", "metadata": {}, "score": "74.131454"}
{"text": "Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity .( adult accrual has completed to Arms A , B , and C as of 8/15/2014 ) .", "label": "", "metadata": {}, "score": "74.22905"}
{"text": "( closed accrual as of 4/4/14 ) ( adult accrual has completed to Arms A , B , and C as of 8/15/2014 ) .Interventions : .", "label": "", "metadata": {}, "score": "74.597305"}
{"text": "Interventions : .Biological : Ipilimumab .Other : Quality - of - Life Assessment .Experimental : Arm D ( age 12 - 17 , high - dose ipilimumab ) .", "label": "", "metadata": {}, "score": "75.21425"}
{"text": "Fluorothymidine Positron Emission Tomography ( FLT PET ) and Blood Oxygen Level Dependent ( BOLD )MRI quantification of tumor responses to predict which patients are likely to achieve a pathologic complete response .", "label": "", "metadata": {}, "score": "75.59203"}
{"text": "Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ .Official Title ICMJE .", "label": "", "metadata": {}, "score": "76.56059"}
{"text": "Kaplan - Meier plot will be generated and two - sided p - values will be reported .If the proportional hazard assumption is appropriate , multivariate Cox proportional hazard models for RFS will be developed at the final analysis .", "label": "", "metadata": {}, "score": "76.56741"}
{"text": "Study Type ICMJE .Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "76.69031"}
{"text": "Behavioral : Mail - based .Participants will receive a standardized mail - based intervention focussing on healthy living .This will include mailings at study entry as well as a two year subscription to health magazine .", "label": "", "metadata": {}, "score": "76.85996"}
{"text": "Life expectancy : .Not specified .Hematopoietic : .Not specified .Hepatic : .Not specified .Renal : .Not specified .Other : .", "label": "", "metadata": {}, "score": "77.01689"}
{"text": "Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity .ARM F : Patients receive induction low - dose ipilimumab IV over 90 minutes on day 1 .", "label": "", "metadata": {}, "score": "77.55261"}
{"text": "Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity .Beginning on week 24 , patients receive maintenance high - dose ipilimumab IV over 90 minutes on day 1 .", "label": "", "metadata": {}, "score": "77.67468"}
{"text": "Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity .Beginning on week 24 , patients receive maintenance high - dose ipilimumab IV over 90 minutes on day 1 .", "label": "", "metadata": {}, "score": "77.67468"}
{"text": "Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity .Beginning on week 24 , patients receive maintenance high - dose ipilimumab IV over 90 minutes on day 1 .", "label": "", "metadata": {}, "score": "77.67468"}
{"text": "Drug : trastuzumab emtansine .3.6 mg / kg intravenously every 3 weeks , 14 cycles .Study Arm ( s ) .Active Comparator : Trastuzumab .", "label": "", "metadata": {}, "score": "77.727295"}
{"text": "Study Arm ( s ) .FLT PET and BOLD MRI scan .All subjects will have the study intervention of FLT PET and BOLD MRI at baseline and after the first cycle of chemotherapy .", "label": "", "metadata": {}, "score": "78.13945"}
{"text": "Medical , surgical or radiation oncologist agrees to subject participation in a diet and physical activity program .Exclusion Criteria : .Insulin requiring diabetes ( telephone directed diet and physical activity changes would be difficult in this population without close coordination with the treating physician ) .", "label": "", "metadata": {}, "score": "78.8854"}
{"text": "Original Secondary Outcome Measures ICMJE .Same as current .Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .", "label": "", "metadata": {}, "score": "79.45316"}
{"text": "Breast Cancer .Intervention ICMJE .Drug : letrozole .Procedure : MRI .Procedure : conventional surgery .Study Arm ( s ) .Experimental : letrozole + MRI + surgery .", "label": "", "metadata": {}, "score": "80.751"}
{"text": "Brief Summary .RATIONALE : Estrogen can cause the growth of breast cancer cells .Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes .", "label": "", "metadata": {}, "score": "80.75108"}
{"text": "Current Primary Outcome Measures ICMJE ( submitted : November 11 , 2010 ) .Clinical response ( partial and complete )[ Time Frame : 6 months ( approximately ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "80.97679"}
{"text": "Patients receive induction low - dose ipilimumab IV over 90 minutes on day 1 .Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "80.98682"}
{"text": "Procedure : adjuvant therapy .Experimental : Tamoxifen plus MPA .Tamoxifen Plus Medroxyprogesterone Acetate ( MPA ) x 5 years .Interventions : .Drug : medroxyprogesterone .", "label": "", "metadata": {}, "score": "80.98764"}
{"text": "Kaplan - Meier plot will be generated and two - sided p - values will be reported .If the proportional hazard assumption is appropriate , multivariate Cox proportional hazard models for OS will be developed at the final analysis .", "label": "", "metadata": {}, "score": "81.753456"}
{"text": "Current Primary Outcome Measures ICMJE ( submitted : January 17 , 2013 ) .Current Secondary Outcome Measures ICMJE ( submitted : January 17 , 2013 ) .", "label": "", "metadata": {}, "score": "81.94562"}
{"text": "Active Comparator : Mail - based .Participants will receive a standardized mail - based intervention focussing on healthy living .This will include mailings at study entry as well as a two year subscription to health magazine .", "label": "", "metadata": {}, "score": "82.25076"}
{"text": "Official Title ICMJE .A Pilot Study of Blood Oxygen Level Dependent Magnetic Resonance Imaging ( BOLD MRI ) and Fluorothymidine Positron Emission Tomography ( FLT PET ) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy .", "label": "", "metadata": {}, "score": "82.253426"}
{"text": "Interferon alfa 2b .INTERFERON ALFA-2B .Interferon Alpha-2b .Intron A .Sch 30500 .Urifron .Viraferon .Study Arm ( s ) .", "label": "", "metadata": {}, "score": "83.42966"}
{"text": "Same as current .Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .", "label": "", "metadata": {}, "score": "83.67135"}
{"text": "L ung cancer remains the most frequent cause of cancer death both in the United States and worldwide .[ 1,2 ] The American Cancer Society ( ACS ) estimates that lung cancer is the third most common cancer in the US , ranking behind prostate cancer and breast cancer ( Table 1 ) .", "label": "", "metadata": {}, "score": "84.43623"}
{"text": "Global quality of life [ Designated as safety issue : No ] .Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .", "label": "", "metadata": {}, "score": "84.804855"}
{"text": "Experimental : Trastuzumab emtansine .Intervention : Drug : trastuzumab emtansine .Not Provided .Estimated Completion Date .March 2023 .Estimated Primary Completion Date .", "label": "", "metadata": {}, "score": "85.35037"}
{"text": "To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .For general information , see Learn About Clinical Studies .", "label": "", "metadata": {}, "score": "85.40548"}
{"text": "Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer .Official Title ICMJE .Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer .", "label": "", "metadata": {}, "score": "85.8342"}
{"text": "This may cause the cancer cells to die .Epirubicin is designed to block the way cancer cells grow and divide , which may slow or stop their growth and spread throughout the body .", "label": "", "metadata": {}, "score": "85.99207"}
{"text": "The ability and willingness to comply with scheduled visits , treatment plan , laboratory tests , and other study procedures .Men or women 18 years of age or older .", "label": "", "metadata": {}, "score": "86.25633"}
{"text": "Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Current Secondary Outcome Measures ICMJE ( submitted : February 19 , 2008 ) .", "label": "", "metadata": {}, "score": "86.39258"}
{"text": "ARM C : Patients receive induction low - dose ipilimumab IV over 90 minutes on day 1 .Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "87.06491"}
{"text": "ARM A : Patients receive induction high - dose ipilimumab intravenously ( IV ) over 90 minutes on day 1 .Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity .", "label": "", "metadata": {}, "score": "87.47865"}
{"text": "Inability to provide informed consent ( e.g. dementia or severe cognitive impairment ) .Gender .Female .Ages .18 Years and older .Accepts Healthy Volunteers .", "label": "", "metadata": {}, "score": "88.887314"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "90.59799"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "90.59799"}
{"text": "Abstract ] J Clin Oncol 24 ( Suppl 18 ) : A-601 , 2006 .", "label": "", "metadata": {}, "score": "92.459076"}
{"text": "Not Provided .Estimated Primary Completion Date .June 2017 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .Eligibility Criteria : .", "label": "", "metadata": {}, "score": "92.63331"}
{"text": "Doxorubicin is designed to stop the growth of cancer cells , which may cause the cells to die .Cyclophosphamide is designed to interfere with the multiplication of cancer cells , which may slow or stop their growth and/or keep them from spreading throughout the body .", "label": "", "metadata": {}, "score": "93.13957"}
{"text": "Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity .( ages 12 - 17 ) .", "label": "", "metadata": {}, "score": "93.739365"}
{"text": "Not Provided .Recruitment Information .Recruitment Status ICMJE .Completed .Enrollment ICMJE .Completion Date .January 2015 .Primary Completion Date .January 2015 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "101.35666"}
{"text": "Not Provided .Recruitment Status ICMJE .Recruiting .Estimated Enrollment ICMJE .Completion Date .Not Provided .Estimated Primary Completion Date .May 2018 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "103.04028"}
{"text": "It is designed to block cells from dividing , which may cause cancer cells to die .Paclitaxel is designed to block cancer cells from dividing , which may cause them to die .", "label": "", "metadata": {}, "score": "108.7431"}
